Look Before Leaping To Reorganize FDA – Former Commissioner McClellan
This article was originally published in The Tan Sheet
Executive Summary
The former commissioner says FDA has to think about getting biggest bang for the buck when considering a reorganization to disease-focused teams, particularly aimed at combination product reviews, which have been problematic because the drug and device review schedules often do not mesh.